Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma

The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic pathway is an att...

Descripción completa

Detalles Bibliográficos
Autores principales: Langendonk, Myra, Smit, Nienke A. M., Plattel, Wouter, Diepstra, Arjan, van Meerten, Tom, Visser, Lydia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699187/
https://www.ncbi.nlm.nih.gov/pubmed/36430230
http://dx.doi.org/10.3390/ijms232213751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699187/
https://www.ncbi.nlm.nih.gov/pubmed/36430230
http://dx.doi.org/10.3390/ijms232213751

Ejemplares similares